BACKGROUND: The effect of oral beta-blocker therapy on long-term mortality in @entity1 with @entity583 ( @entity583 ) who are treated with primary percutaneous coronary intervention (PCI) and who have preserved left ventricular ejection fraction (LVEF) remains unclear. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies evaluating the effect of oral beta-blocker therapy in @entity1 with @entity583 who underwent primary PCI and who had preserved LVEF. The primary outcome was all-cause mortality. Randomized controlled trials and the observational studies that reported an adjusted hazard ratio (or hazard ratio in the propensity score-matched @entity1 ) with follow-up duration equal to or more than 6 months were included. Pooled hazard ratio with 95% confidence interval (CI) was calculated using a random effect model. RESULTS: No randomized controlled trials met the inclusion criteria. Seven observational studies totaling 10 857 @entity1 met the inclusion criteria. Follow-up duration ranged from 6 months to 5.2 years. Preserved LVEF was defined as 40% in 4 studies and 50% in 3 studies. Based on the pooled estimate, oral beta-blocker therapy was associated with a reduction in all-cause mortality (combined hazard ratio 0.79, 95% CI 0.65-0.97). CONCLUSION: This meta-analysis demonstrates that oral beta-blocker therapy is associated with decreased all-cause mortality in @entity1 with @entity583 who are treated with primary PCI and who have preserved LVEF. This supports the current American College of Cardiology Foundation/American Heart Association 2013 Guideline for the Management of @entity583 .

Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation XXXX With Preserved Systolic Function? A Meta-Analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']
@entity583 :: (MESH:D009203,Disease) :: ['Myocardial Infarction']
